HDP1 Stock Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.00 |
| 52 Week High | US$37.16 |
| 52 Week Low | US$19.52 |
| Beta | 0.72 |
| 1 Month Change | -18.41% |
| 3 Month Change | -30.60% |
| 1 Year Change | -23.27% |
| 3 Year Change | -63.09% |
| 5 Year Change | 25.01% |
| Change since IPO | -62.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| HDP1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.5% | -4.9% | -1.5% |
| 1Y | -23.3% | -19.9% | 0.9% |
Return vs Industry: HDP1 underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: HDP1 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| HDP1 volatility | |
|---|---|
| HDP1 Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HDP1's share price has been volatile over the past 3 months.
Volatility Over Time: HDP1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 525 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| HDP1 fundamental statistics | |
|---|---|
| Market cap | €2.62b |
| Earnings (TTM) | -€278.86m |
| Revenue (TTM) | €170.74m |
15.4x
P/S Ratio-9.4x
P/E RatioIs HDP1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HDP1 income statement (TTM) | |
|---|---|
| Revenue | US$181.74m |
| Cost of Revenue | US$0 |
| Gross Profit | US$181.74m |
| Other Expenses | US$478.55m |
| Earnings | -US$296.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | 100.00% |
| Net Profit Margin | -163.32% |
| Debt/Equity Ratio | 157.6% |
How did HDP1 perform over the long term?
See historical performance and comparison